SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
Open Access
- 31 August 2020
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 227
Abstract
Tuberculosis remains the world’s top infectious killer: it caused a total of 1.5 million deaths and 10 million people fell ill with TB in 2018. Thanks to TB diagnosis and treatment, mortality has been falling in recent years, with an estimated 58 million saved lives between 2000 and 2018. However, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains is a major concern that might reverse this progress. Therefore, the development of new drugs acting upon novel mechanisms of action is a high priority in the global health agenda. With the approval of bedaquiline, which targets mycobacterial energy production, and delamanid, which targets cell wall synthesis and energy production, the energy-metabolism in Mtb has received much attention in the last decade as a potential target to investigate and develop new antimycobacterial drugs. In this review, we describe potent anti-mycobacterial agents targeting the energy-metabolism at different steps with a special focus on structure-activity relationship (SAR) studies of the most advanced compound classes.Keywords
This publication has 151 references indexed in Scilit:
- Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malariaProceedings of the National Academy of Sciences, 2012
- MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212Antimicrobial Agents and Chemotherapy, 2012
- Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for AccumulationAntimicrobial Agents and Chemotherapy, 2011
- Kinetic and Chemical Mechanism of Malate Synthase from Mycobacterium tuberculosisBiochemistry, 2011
- Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontierTrends in Microbiology, 2011
- Inhibition of the M. tuberculosis 3β-hydroxysteroid dehydrogenase by azasteroidsBioorganic & Medicinal Chemistry Letters, 2011
- Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone OxidoreductaseJournal of Biological Chemistry, 2011
- Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infectionProceedings of the National Academy of Sciences, 2010
- Mycobacterial persistence requires the utilization of host cholesterolProceedings of the National Academy of Sciences, 2008
- The product complex of M. tuberculosis malate synthase revisitedProtein Science, 2006